摘要
目的 明确CD25抗原分子表达在急性髓细胞白血病(AML)[非急性早幼粒细胞白血病(APL)且非核心结合因子相关急性髓细胞白血病(CBF-AML)]中的临床意义.方法 收集2012年1月至2017年8月郑州大学第一附属医院171例AML(非APL且非CBF-AML)患者的临床及随访资料并回顾性分析CD25在AML(非APL且非CBF-AML)中的表达情况及患者的一般临床特点.结果 在AML(非APL且非CBF-AML)中,CD25阳性组患者完全缓解比仅为8/18,而CD25阴性组患者的完全缓解率达71.24%(109/153),差异有统计学意义(χ2=5.353,P=0.021);复发患者在CD25阳性组占比高达6/8,在CD25阴性组中复发率为31.19%(34/109),差异有统计学意义(χ2=6.357,P=0.012).CD25阳性患者较CD25阴性患者有更短的无复发生存期(χ2=13.68,P〈0.001)、更短的总生存期(χ2=12.26,P〈0.001).CD25阳性组预后与高危组预后相当,且与低危组、中危组比较差异有统计学意义(P〈0.05).结论 在AML(非APL且非CBF-AML)中,CD25阳性表达的患者预后不良,其预后与现有预后分层中的高危组相当,可以作为现有预后分层的有机补充.
Objective To explicit the prognostic value of CD 25 antigen molecule expression in acute myelocytic leukemia ( AML) , except acute promyelocytic leukemia ( APL) and core binding factor positive acute myelocytic leukemia ( CBF-AML ) .Methods The clinical and follow-up data of 171 patients with AML ( non-APL and non-CBF-AML) in the First Affiliated Hospital of Zhengzhou University From January 2012 to August 2017 were collected , and the expression of CD 25 and the general clinical characteristics of patients were retrospectively analyzed .Results In patients with AML ( non-APL an non-CBF-AML) , the complete remission rate in CD25 positive group was only 8/18, and it was 71.24%(109/153) in CD25 negative group, the difference was statistically significant (χ2 =5.353, P=0.021) . The recurrence rate in CD25 positive goup was 6/8, and it was 31.19% (34/109) in CD25 negative group, the difference was statistically significant (χ2 =6.357, P=0.012).CD25-positive patients had shorter relapse-free survival (RFS,χ2 =13.68, P〈0.001) and shorter overall survival (OS,χ2 =12.26, P〈0.001) than CD25-negative patients.The prognosis of CD25 positive group was similar to that of high-risk group, and it was significantly different from those of low-risk group and the middle-risk group (P〈0.05).Conclusions InAML (non-APL and non CBF-AML), patients with positive expression of CD25 have a poor prognosis , and their prognosis is comparable to those of high-risk group in the existing prognostic stratification , and can be used as an organic supplement to the existing prognostic stratification .
作者
胡营涛
马杰
李亚雨
刘晓艳
李宁
孙慧
刘延方
谢新生
万鼎铭
姜中兴
孙玲
李涛
Hu Yingtao;Ma Jie;Li Yayu;Liu Xiaoyan;Li Ning;Sun Hui;Liu Yanfang;Xie Xinsheng;Wan Dingming;Jiang Zhongxing;Sun Ling;Li Tao(Deoartment of Hematology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China(Hu YT,Ma J,Li YY,Liu XY,Li L,Sun H,Liu YF,Xie XS,Wan DM,Jiang ZX,Sun L;Institute of Hematology,Zhengzhou University,Zhengzhou 450052,China(Li T)])
出处
《中国实用医刊》
2018年第19期14-17,共4页
Chinese Journal of Practical Medicine